Trials that use: Cox proportional-hazards model
New to this method? Read the tutorial →
318 results
- A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST): Complete Statistical AnalysisIndependent statistical analysis of A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval,…
- A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis: Complete Statistical AnalysisIndependent statistical analysis of A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD): Complete Statistical AnalysisIndependent statistical analysis of A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD): primary endpoint results, effect estimate with…
- A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer: primary endpoint results, effect…
- A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1): Complete Statistical AnalysisIndependent statistical analysis of A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine…
- A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.: Complete Statistical AnalysisIndependent statistical analysis of A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces: Complete Statistical AnalysisIndependent statistical analysis of A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces: primary endpoint results, effect estimate…
- A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC): Complete Statistical AnalysisIndependent statistical analysis of A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Trial of FANG™ Vaccine for Participants With Ovarian Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Trial of FANG™ Vaccine for Participants With Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01309230).
- A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- A Trial of Telemonitoring in Adults With Heart Failure: Complete Statistical AnalysisIndependent statistical analysis of A Trial of Telemonitoring in Adults With Heart Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01393314).
- A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder: Complete Statistical AnalysisIndependent statistical analysis of A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder: primary endpoint results, effect estimate with confidence…
- ACCELERATEComplete statistical analysis of ACCELERATE (NCT01687998), a randomized phase 3 study of evacetrapib versus placebo in high-risk vascular disease, including trial design, composite cardiovascular endpoints, Cox modeling, ANOVA, confidence intervals, p-values, and…
- Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda: Complete Statistical AnalysisIndependent statistical analysis of Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing’s Sarcoma, and Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer: primary endpoint results, effect estimate…
- Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit: Complete Statistical AnalysisIndependent statistical analysis of Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- ADVANCEIndependent statistical analysis of the phase 3 ADVANCE trial of peginterferon beta-1a versus placebo in relapsing multiple sclerosis, covering negative binomial rate ratios for annualized relapse rate, Cox hazard ratios, lesion mean…
- Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings: Complete Statistical AnalysisIndependent statistical analysis of Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- ALTA-3Independent statistical analysis of A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- ALTISSIMOIndependent statistical analysis of A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene: Complete Statistical AnalysisIndependent statistical analysis of An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma…
- An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator’s Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026): Complete Statistical AnalysisIndependent statistical analysis of An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026): primary…
- Analytical Treatment Interruption (ATI) to Assess the Immune System’s Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study: Complete Statistical AnalysisIndependent statistical analysis of Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study: primary endpoint results,…
- ANGELIndependent statistical analysis of A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer: primary endpoint results, effect estimate with confidence…
- AREDS2A complete statistical analysis of AREDS2, the randomized phase 3 trial evaluating lutein/zeaxanthin and DHA/EPA in people at moderate to high risk for progression of age-related macular degeneration, including time-to-event methodology, hazard…
- ARIEL3Independent statistical analysis of the phase 3 ARIEL3 trial of rucaparib as switch maintenance after platinum in relapsed high-grade serous or endometrioid ovarian cancer, including trial design, progression-free survival, Cox modeling, hazard…
- ARISTOTLEIndependent statistical analysis of ARISTOTLE (NCT00412984), including trial design, time-to-event endpoints, Cox proportional-hazards methodology, hazard ratios, confidence intervals, safety results, and statistical interpretation.
- Arm Circumference Measurement With or Without Bioimpedance Spectroscopy in Finding Lymphedema Early in Patients With Stage I-III Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Arm Circumference Measurement With or Without Bioimpedance Spectroscopy in Finding Lymphedema Early in Patients With Stage I-III Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- ASCLEPIOS IAn independent statistical analysis of ASCLEPIOS I, the phase 3 double-blind comparison of ofatumumab and teriflunomide in relapsing multiple sclerosis, covering the negative binomial relapse-rate analysis, Cox models for pooled disability endpoints,…
- ASCLEPIOS IIAn independent statistical analysis of ASCLEPIOS II, the phase 3 trial of subcutaneous ofatumumab versus teriflunomide in relapsing multiple sclerosis: negative binomial annualized relapse rate, Cox models for confirmed disability, pooled analyses…
- ASPECCTIndependent statistical analysis of ASPECCT, the randomized phase 3 comparison of panitumumab and cetuximab in patients with KRAS wild-type metastatic colorectal cancer, including non-inferiority analysis, hazard ratios, response, patient-reported outcomes, and safety.
- ASPENIndependent statistical analysis of the phase 3 ASPEN trial of brensocatib 10 mg and 25 mg versus placebo in non-cystic fibrosis bronchiectasis, covering negative binomial rate ratios for pulmonary exacerbations, Cox, logistic…
- Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo: Complete Statistical AnalysisIndependent statistical analysis of Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Assessing PA-824 for Tuberculosis (the APT Trial): Complete Statistical AnalysisIndependent statistical analysis of Assessing PA-824 for Tuberculosis (the APT Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02256696).
- Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF): Complete Statistical AnalysisIndependent statistical analysis of Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00252967).
- Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Avelumab in First-line NSCLC (JAVELIN Lung 100): Complete Statistical AnalysisIndependent statistical analysis of Avelumab in First-line NSCLC (JAVELIN Lung 100): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02576574).
- Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100): Complete Statistical AnalysisIndependent statistical analysis of Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300): Complete Statistical AnalysisIndependent statistical analysis of Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02625623).
- AXELIndependent statistical analysis of An Observational Study of First-Line Capecitabine Based Chemotherapy in Participants With Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00920816).
- Azacitidine and Pembrolizumab in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Azacitidine and Pembrolizumab in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03264404).
- Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: primary endpoint…
- AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02513563).
- BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Be Fit in Residency: a Randomized Controlled Trial of an Activity Device Among Medicine Residents: Complete Statistical AnalysisIndependent statistical analysis of Be Fit in Residency: a Randomized Controlled Trial of an Activity Device Among Medicine Residents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…